Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852651 | 0.94 | KCNH2 (0.35) | PIM1PIM3MEN1KMT2ATDP1 | |
| Carbamic Acid SCHEMBL5064953 | 0.92 | PIM1 (0.35) | PIM1PIM3MEN1KMT2ATDP1 | |
| Acetamide SCHEMBL6972197 | 0.89 | TDP1 (0.41) | MEN1KMT2ATDP1P2RX3 | |
| SCHEMBL14439810 | 0.88 | MEN1 (0.37) | PIM1PIM3MEN1KMT2ATDP1 | |
| SCHEMBL6970008 | 0.87 | PIM1 (0.36) | PIM1PIM3MEN1KMT2ATDP1 | |
| Capravirine SCHEMBL40347 | 0.87 | PIM1 (0.35) | PIM1PIM3MEN1KMT2ATDP1 | |
| Capravirine SCHEMBL4656686 | 0.87 | PIM1 (0.35) | PIM1PIM3MEN1KMT2ATDP1 | |
| SCHEMBL6966848 | 0.87 | TDP1 (0.42) | MEN1KMT2ATDP1RHEB | |
| SCHEMBL4680536 | 0.86 | MEN1 (0.38) | MEN1KMT2ATDP1P2RX3RHEB | |
| SCHEMBL8345211 | 0.86 | TBXA2R (0.40) | MEN1KMT2ATDP1P2RX3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4342545-A2 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | Elian LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4299563-A2 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | Japan Tobacco Inc. (JP) | 2024-01-03 | — | — | EP | disclosed |
| EP-3166680-B1 | ANTI-HSV PRE-EXPOSURE PROPHYLAXIS | ELIAN LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3281939-B1 | COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230310439-A1 | VIRAL PROPHYLAXIS TREATMENT METHODS AND PRE-EXPOSURE PROPHYLAXIS KITS | ELIAN LLC | 2023-10-05 | — | — | US | disclosed |
| US-20230302154-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | UNIVERSITY OF CONNECTICUT | 2023-09-28 | — | — | US | disclosed |
| US-11696918-B2 | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | ELIAN LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086152-A1 | SYSTEMS AND METHODS FOR THE PRODUCTION OF METHEMOGLOBIN AND ITS DERIVATIVES | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-03-09 | — | — | US | disclosed |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | SHIONOGI & CO., LTD. (JP) | 2006-02-09 | — | — | US | disclosed |
| US-20060019906-A1 | Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050288326-A1 | Combination therapy | SHIONOGI & CO., LTD. (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1544199-A1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | PIM1 129/4885PIM3 409/4885MEN1 3959/4885 |
| US-20050288326-A1 | Combination therapy | TYMP, TPMT, PNP | PIM1 67/4885PIM3 82/4885MEN1 4481/4885 |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | PIM1 276/4885PIM3 578/4885MEN1 4589/4885 |
| US-20060019906-A1 | Novel 4-oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, PIP4K2B, IMPDH2 | PIM1 134/4885PIM3 211/4885MEN1 4674/4885 |
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | RPL35, RPL7, TYMP | PIM1 902/4885PIM3 774/4885MEN1 4308/4885 |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | PIM1 129/4885PIM3 409/4885MEN1 3959/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | PIM1 502/4885PIM3 852/4885MEN1 4618/4885 |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, CDKL4, IMPDH2 | PIM1 173/4885PIM3 329/4885MEN1 4685/4885 |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | IMPDH1, IMPDH2, TYMP | PIM1 204/4885PIM3 317/4885MEN1 4764/4885 |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | KCNQ2, RCC1, SFPQ | PIM1 2367/4885PIM3 1922/4885MEN1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.